HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

David H Sherr Selected Research

Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)

11/2021The aryl hydrocarbon receptor suppresses immunity to oral squamous cell carcinoma through immune checkpoint regulation.
3/2019Inflammatory breast cancer: Activation of the aryl hydrocarbon receptor and its target CYP1B1 correlates closely with Wnt5a/b-β-catenin signalling, the stem cell phenotype and disease progression.
5/2018Towards Resolving the Pro- and Anti-Tumor Effects of the Aryl Hydrocarbon Receptor.
1/2018Detection of aryl hydrocarbon receptor agonists in human samples.
11/2017Targeting STUB1-tissue factor axis normalizes hyperthrombotic uremic phenotype without increasing bleeding risk.
11/2016An Aryl Hydrocarbon Receptor-Mediated Amplification Loop That Enforces Cell Migration in ER-/PR-/Her2- Human Breast Cancer Cells.
3/2016The role of the aryl hydrocarbon receptor in the development of cells with the molecular and functional characteristics of cancer stem-like cells.
1/2016The Aryl Hydrocarbon Receptor is a Critical Regulator of Tissue Factor Stability and an Antithrombotic Target in Uremia.
1/2016Role for the Aryl Hydrocarbon Receptor and Diverse Ligands in Oral Squamous Cell Carcinoma Migration and Tumorigenesis.
11/2014In silico identification of an aryl hydrocarbon receptor antagonist with biological activity in vitro and in vivo.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


David H Sherr Research Topics

Disease

24Neoplasms (Cancer)
11/2021 - 11/2003
9Breast Neoplasms (Breast Cancer)
11/2016 - 01/2005
9Carcinogenesis
01/2016 - 01/2005
2Squamous Cell Carcinoma of Head and Neck
11/2021 - 01/2016
2Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental)
12/2020 - 09/2010
2Autoimmune Diseases (Autoimmune Disease)
12/2020 - 01/2017
2Disease Progression
03/2019 - 03/2017
2Inflammatory Breast Neoplasms
03/2019 - 03/2016
2Neoplasm Metastasis (Metastasis)
05/2018 - 11/2016
2Uremia
11/2017 - 01/2016
2Thrombosis (Thrombus)
11/2017 - 01/2016
2Inflammation (Inflammations)
09/2010 - 12/2003
2Hematologic Neoplasms (Hematological Malignancy)
08/2006 - 06/2005
1Lymphatic Metastasis
03/2019
1Wounds and Injuries (Trauma)
05/2018
1Hemorrhage
11/2017
1Chronic Renal Insufficiency
11/2017
1Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease)
01/2017
1Mouth Neoplasms (Oral Cancer)
01/2016
1Prostatic Neoplasms (Prostate Cancer)
01/2016
1Chronic Kidney Failure (Chronic Renal Failure)
01/2016
1Triple Negative Breast Neoplasms
11/2014
1Immunoglobulin Light-chain Amyloidosis
05/2012
1Lymphoma (Lymphomas)
05/2012
1Graft vs Host Disease (Graft-Versus-Host Disease)
09/2010
1Atrophy
05/2010
1Hypoxia (Hypoxemia)
07/2009
1Carcinoma (Carcinomatosis)
06/2008

Drug/Important Bio-Agent (IBA)

16Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA
11/2021 - 01/2005
9LigandsIBA
05/2018 - 11/2005
7CarcinogensIBA
12/2020 - 01/2005
5Transcription Factors (Transcription Factor)IBA
01/2018 - 11/2005
5NF-kappa B (NF-kB)IBA
06/2008 - 01/2005
4Proteins (Proteins, Gene)FDA Link
11/2017 - 06/2008
4Polycyclic Aromatic Hydrocarbons (Polynuclear Aromatic Hydrocarbons)IBA
12/2007 - 01/2005
3Biological ProductsIBA
03/2017 - 11/2014
3Cytochrome P-450 Enzyme System (Cytochrome P450)IBA
05/2008 - 11/2003
2AntigensIBA
12/2020 - 11/2003
2Messenger RNA (mRNA)IBA
03/2019 - 01/2016
2Cadherins (E-Cadherin)IBA
05/2018 - 12/2007
2Small Interfering RNA (siRNA)IBA
05/2018 - 03/2016
2Thromboplastin (Tissue Factor)IBA
11/2017 - 01/2016
2DioxinsIBA
01/2017 - 05/2010
2EnzymesIBA
11/2016 - 11/2003
2Biomarkers (Surrogate Marker)IBA
03/2016 - 01/2016
2Cytochrome P-450 CYP1A1 (CYP1A1)IBA
03/2016 - 05/2008
2Pharmaceutical PreparationsIBA
01/2016 - 11/2003
2XenobioticsIBA
02/2009 - 12/2007
2Environmental CarcinogensIBA
05/2008 - 01/2005
29,10-Dimethyl-1,2-benzanthraceneIBA
12/2007 - 03/2006
2Environmental Pollutants (Pollutants, Environmental)IBA
12/2007 - 08/2005
2Cyclin D1IBA
08/2005 - 01/2005
1Immune Checkpoint InhibitorsIBA
11/2021
1Myelin-Oligodendrocyte GlycoproteinIBA
12/2020
1T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA
12/2020
1CateninsIBA
03/2019
1Polychlorinated Dibenzodioxins (TCDD)IBA
05/2018
1ThrombospondinsIBA
05/2018
1Fibronectins (Fibronectin)IBA
05/2018
1matrigelIBA
05/2018
13,3'-diindolylmethane (diindolylmethane)IBA
05/2018
1DNA (Deoxyribonucleic Acid)IBA
01/2017
1Polychlorinated Biphenyls (PCBs)IBA
01/2017
1KynurenineIBA
11/2016
1Tryptophan (L-Tryptophan)FDA Link
11/2016
1xanthurenic acidIBA
11/2016
1Tryptophan Oxygenase (Tryptophan 2,3 Dioxygenase)IBA
11/2016
1Doxorubicin (Adriamycin)FDA LinkGeneric
01/2016
1VaccinesIBA
05/2012
1Amyloid (Amyloid Fibrils)IBA
05/2012
1Immunoglobulin Light Chains (Immunoglobulin Light Chain)IBA
05/2012
1Peptides (Polypeptides)IBA
05/2012
1HLA-A2 Antigen (HLA A2 Antigen)IBA
05/2012
1Combined VaccinesIBA
05/2012
1Cytochrome P-450 CYP1B1IBA
05/2012
1interleukin-21 (interleukin 21)IBA
09/2010
1Interleukin-10 (Interleukin 10)IBA
09/2010
1Estrogen Receptor alphaIBA
07/2009
1Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA
07/2009
1Pregnane X ReceptorIBA
07/2009
1PolyphenolsIBA
12/2007
1Casein Kinase II (Casein Kinase 2)IBA
12/2007
1TeaIBA
12/2007
1GW 7845IBA
07/2007
1PPAR gammaIBA
07/2007
1PPAR-gamma AgonistsIBA
08/2006
1Peroxisome Proliferator-Activated Receptors (PPAR)IBA
08/2006
1AgarIBA
03/2006
1Dimethyl Sulfoxide (DMSO)FDA LinkGeneric
03/2006
1FlavonoidsIBA
01/2006
1galanginIBA
01/2006
1Estrogen ReceptorsIBA
01/2006
1CyclinsIBA
01/2006
1Cyclin-Dependent Kinase Inhibitor p27IBA
08/2005
1HLA-A Antigens (HLA-A)IBA
06/2005
1Neoplasm Antigens (Tumor Antigens)IBA
06/2005
1EpitopesIBA
06/2005

Therapy/Procedure

6Therapeutics
05/2018 - 11/2003
1Precision Medicine
01/2016
1Immunomodulation
11/2014